Part III – Renal Cell Carcinoma

Select Publications


Escudier BJ et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) — PISCES study, NCT 01064310. *Proc ASCO* 2012;Abstract CRA4502.


Hutson TE et al. A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). *Proc ASCO* 2012;Abstract TPS4686.


Motzer RJ et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. *Proc ASCO* 2012;Abstract 4501.

Nakamura K et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. *Cancer Res* 2006;66(18):9134-42.


